4D Molecular Therapeutics, Inc.
US ˙ NasdaqGS ˙ US35104E1001

SecurityFDMT / 4D Molecular Therapeutics, Inc.
InstitutionTrexquant Investment LP
Latest Disclosed Ownership0 shares
Latest Disclosed Value $ 0
Trexquant Investment LP closes position in FDMT / 4D Molecular Therapeutics, Inc.

On May 15, 2026 - Trexquant Investment LP filed a 13F-HR form disclosing ownership of 0 shares of 4D Molecular Therapeutics, Inc. (US:FDMT) valued at $0 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 13,229 shares of 4D Molecular Therapeutics, Inc.. The current value of the position is $0 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F 4D MOLECULAR THERAPEUTICS IN COM 35104E100 0 -100.00 0
2026-02-17 2025-12-31 13F 4D MOLECULAR THERAPEUTICS IN COM 35104E100 13,229 -68,125 -83.74 99 -85.98 0.0009
2025-11-14 2025-09-30 13F 4D MOLECULAR THERAPEUTICS IN COM 35104E100 81,354 81,354 707 0.0073
2024-11-12 2024-09-30 13F 4D MOLECULAR THERAPEUTICS IN COM 35104E100 0 -28,385 -100.00 0 -100.00
2024-08-13 2024-06-30 13F 4D MOLECULAR THERAPEUTICS IN COM 35104E100 28,385 28,385 596 0.0091
2024-02-09 2023-12-31 13F 4D MOLECULAR THERAPEUTICS IN COM 35104E100 0 -44,443 -100.00 0 -100.00
2023-11-13 2023-09-30 13F 4D MOLECULAR THERAPEUTICS IN COM 35104E100 44,443 44,443 566 0.0142
2023-05-15 2023-03-31 13F 4D MOLECULAR THERAPEUTICS IN COM 35104E100 0 -18,525 -100.00 0 -100.00
2023-02-13 2022-12-31 13F 4D MOLECULAR THERAPEUTICS IN COM 35104E100 18,525 -6,593 -26.25 411 103.47 0.0117
2022-11-14 2022-09-30 13F 4D MOLECULAR THERAPEUTICS IN COM 35104E100 25,118 -25,662 -50.54 202 -42.94 0.0071
2022-08-11 2022-06-30 13F 4D MOLECULAR THERAPEUTICS IN COM 35104E100 50,780 50,780 354 0.0159
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.